

ADDENDUM NO. 2

DATE: January 24, 2020

TO: All Potential Proposers

FROM: Penny Owens, Assistant Purchasing Agent, City of Knoxville

SUBJECT: Addendum No. 2 – RFP for Workers’ Compensation Pharmacy Services

RFPs TO BE OPENED: January 28, 2020 at 11:00:00 a.m. (Eastern Time)

This addendum is being published to address the following questions received regarding the above referenced RFP. This addendum becomes a part of the contract documents and modifies the original specifications as noted.

Question #1: On the “Vendor Requested Data Elements” document, please clarify Prescriber Specialty

Response: Provide the prescribing physician’s specialty (i.e. cardiology, neurology.) It’s often passed via a code, hence the need for the crosswalk.

Question #2: In the Submission Form S-2 Questionnaire
Under Financial #8 (b & d):

Can we receive further clarification. We understand ANDA is an abbreviated new drug application that is an application for a U.S generic drug for an existing brand name drug, our brand/generic designation is based on the nationally recognized authority Medi-Span used by the majority of all pharmacy chains. Would you allow the brand/generic designation to be based on the Medi-Span multi-source indicator?

Response: Medi-Span includes ANDA. The City does not want to pay for drugs that haven’t been approved by the FDA. Please include how will you comply when using Medi-Span.

Question #3: In the Submission Form S-2 Questionnaire
Under Financial #13:

In regards to the question “Provide information on the performance guarantees your firm will make, including penalties for failure to meet standards.” what performance guarantees do you have in place today?

Response: Current guarantees are based on network penetration, generic substitution rate, generic dispensing rate, electronic system availability, and claims adjudication accuracy.

Question #4: In Financial section, question 8.e.; MAC logic is mentioned. In prior questions, MAC is not mentioned. Please explain.

Response: MAC is more commonly used for generic pricing and we will agree to the lesser of MAC or AWP pricing for generics. MAC is also helpful in newly released generic medications that would not be listed on the pricing spreadsheet.

Question #5: In Financial section, question 8.g.; Where does the U&C rate come from? Please explain why U&C rate may apply when there is a fee schedule.

Response: This question was overlooked given that we shouldn't have any medication that isn't dispensed from the pharmacy. Question 8.g. in the Financial Section of the Submission Form S-2 Questionnaire is hereby deleted.

END OF ADDENDUM 2